Skip to main content
Midas Edge

PROVECTUS BIOPHARMACEUTICALS, INC.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

PVCT$0.04-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025

Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Noncontrolling
SharesAmountSharesAmountSharesAmountCapitalLossDeficitInterestTotal
Balance at January 1, 2025956,985$95713,106,223$13,106420,279,879$420,280$251,090,027$(60,741)$(257,422,961)$(9,893)$(5,969,225)
Issuance of common stock of majority owned subsidiary------634,782--65,218700,000
Conversion of 2022 Notes and interest to Series D-1 Preferred Stock--365,400365--1,046,329---1,046,694
Stock-based compensation:-
Amortization of stock options------315,100---315,100
Comprehensive loss:-
Net loss--------(1,140,108)(21,494)(1,161,602)
Other comprehensive income-------52--52
Balance at March 31, 2025956,98595713,471,62313,471420,279,879420,280253,086,238(60,689)(258,563,069)33,831(5,068,981)
Conversion of 2022 Notes and interest to Series D-1 Preferred Stock--252,940253--723,656---723,909
Stock-based compensation:
Amortization of stock options------322,070---322,070
Comprehensive loss:
Net loss--------(1,814,420)(37,661)(1,852,081)
Other comprehensive income-------328--328
Balance at June 30, 2025956,985$95713,724,563$13,724420,279,879$420,280$254,131,964$(60,361)$(260,377,489)$(3,830)$(5,874,755)

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2024

Preferred Stock Series D · Preferred Stock Series D-1 · Common Stock · Additional Paid-In · Accumulated Other Comprehensive · Accumulated · Noncontrolling
Shares · Amount · Shares · Amount · Shares · Amount · Capital · Loss · Deficit · Interest · Total
Balance at January 1, 202412,373,247$12,37310,361,097$10,361419,522,119$419,522$244,714,967$(60,165)$(252,690,409)$-$(7,593,351)
Conversion of 2022 Notes and interest to Series D-1 Preferred Stock--226,474226--647,935---648,161
Comprehensive loss:
Net loss--------(504,042)-(504,042)
Other comprehensive loss-------(415)--(415)
Balance at March 31, 202412,373,24712,37310,587,57110,587419,522,119419,522245,362,902(60,580)(253,194,451)-$(7,449,647)
Forfeited shares of Series D Preferred Stock(11,416,262)(11,416)----11,416----
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock--1,141,6261,141--(1,141)----
Conversion of 2022 Notes and interest to Series D-1 Preferred Stock--273,691274--783,022---783,296
Comprehensive loss:-
Net loss--------(846,848)-(846,848)
Other comprehensive income-------126--126
Balance at June 30, 2024956,985$95712,002,888$12,003419,522,119$419,522$246,156,198$(60,454)$(254,041,299)$-$(7,513,073)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.